Lynn Morris to Immunoglobulin G
This is a "connection" page, showing publications Lynn Morris has written about Immunoglobulin G.
Connection Strength
2,169
-
IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. PLoS Pathog. 2019 12; 15(12):e1008064.
Score: 0,588
-
HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS Pathog. 2018 04; 14(4):e1006987.
Score: 0,523
-
Functional consequences of allotypic polymorphisms in human immunoglobulin G subclasses. Immunogenetics. 2023 02; 75(1):1-16.
Score: 0,176
-
HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function. Front Immunol. 2021; 12:733958.
Score: 0,166
-
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 02; 17(2):e1003038.
Score: 0,149
-
Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. AIDS. 2017 10 23; 31(16):2199-2209.
Score: 0,127
-
Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. AIDS. 2016 Apr 24; 30(7):1005-14.
Score: 0,114
-
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008 Dec; 82(24):12449-63.
Score: 0,068
-
Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms. Sci Rep. 2022 10 01; 12(1):16473.
Score: 0,045
-
Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission. J Virol. 2022 02 23; 96(4):e0193421.
Score: 0,042
-
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 09 18; 11(510).
Score: 0,036
-
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018 07; 5(7):e366-e378.
Score: 0,033
-
Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage. PLoS One. 2015; 10(7):e0131906.
Score: 0,027
-
A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. J Biol Chem. 2014 Oct 24; 289(43):29912-26.
Score: 0,025
-
Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology. 2012 Nov 25; 433(2):410-20.
Score: 0,022
-
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 2008 Dec; 82(23):11651-68.
Score: 0,017
-
Human herpesvirus-8 antibodies and DNA in HIV-1 infected patients in South Africa. Epidemiol Infect. 2003 Dec; 131(3):1125-9.
Score: 0,012